Merck(US:MRK) Guo Ji Jin Rong Bao·2025-11-08 12:18Core Insights - Merck, a leading global biopharmaceutical company, showcased its commitment to high-quality healthcare development in China at the 8th China International Import Expo with the theme "Innovative Science, Healthy Future" [1] - The company aims to enhance deep communication and collaboration within the pharmaceutical industry and accelerate the application of medical innovations in the Chinese market [1] Group 1: Company Overview - Merck has over 130 years of history and operates in various fields including prescription drugs, vaccines, and animal health products [3] - Since entering the Chinese market in 1992, Merck has viewed China as a key component of its global growth strategy [3] - The company has participated in the Import Expo for seven consecutive years, using it as a platform for innovation display, industry linkage, and value realization [3] Group 2: Product Innovations - At this year's Import Expo, Merck presented approximately 30 innovative drugs and vaccines targeting critical public health issues, including cancer, infections, diabetes, and rare diseases [4] - Several products made their debut at the expo, including innovative drugs for treating drug-resistant infections and rare diseases [4] - Merck's HPV vaccine was approved this year for male prevention of HPV-related cancers and diseases, and the company has received approvals for 32 indications for cancer treatment drugs as of August this year [4] Group 3: Collaborations and Community Engagement - Merck has engaged in multiple R&D collaborations with local pharmaceutical companies such as Kelun-Biotech and Hengrui Medicine, focusing on cardiovascular, metabolic, and oncology fields [4] - The company promotes health education, emphasizing that "everyone is the first responsible person for their own health" [5] - Merck is committed to accelerating innovation introduction and deepening local cooperation in China, contributing to the construction of a "Healthy China" [5]